Scuttlebutt

Scuttlebutt

OpenEvidence CEO: doctors using the app will treat 300M Americans this year

10 takeaways: why 88% of second opinions differ from the first, how the iTunes model won medical journals as partners, and why 1 in 3 clinical trials stop early

Scuttlebutt's avatar
Scuttlebutt
Oct 01, 2026
∙ Paid

Talks at GS · Sep 30, 2026 · recorded Jul 15, 2026 · 18m · 9m saved

With Daniel Nadler, Co-Founder and CEO of OpenEvidence

OpenEvidence CEO: doctors using the app will treat 300M Americans this year

OpenEvidence handled 1.5 million queries from license-verified doctors in the US in a single day, in a country with 1 million physicians, according to its chief executive, Daniel Nadler.

AI companies have mostly trained on published work without paying for it and fought publishers in court. Nadler went the other way: he signed The New England Journal of Medicine and other medical bodies as paid partners, and in some cases shareholders, so doctors searching OpenEvidence see the full research papers.

"So, this year, there are going to be 300 million Americans who were treated by a physician who used OpenEvidence to make the treatment decision." — Daniel Nadler

Daniel Nadler, co-founder and CEO of OpenEvidence, on Talks at GS, founded his first company, Kensho Technologies, with Goldman Sachs as its incubator and sold it in 2018 for $700 million. Google is now OpenEvidence's largest investor.

The full interview is covered here so you can skip it. 18 minutes of audio, 9 minutes of reading.

Here are the 10 takeaways that matter.


This Scuttlebutt Summary is available in full to premium subscribers. If you're not one already, please consider subscribing to keep reading.


Key Takeaways

  • OpenEvidence handled 1.5M verified doctor queries in the US in one day, and Nadler said it is now the default source of medical knowledge for US physicians

  • A study he cited found 88% of second opinions differ from the first, and one in five overturn it

  • New treatments take about 17 years to reach routine care; he wants that cut to 17 hours

  • OpenEvidence pays medical journals and societies instead of scraping them, a model he took from Apple's iTunes deals

    • Its users get full papers and charts, not only the summaries most AI models train on

  • Society spends $50B a year on clinical trials, and 1 in 3 stop early, mainly because they cannot find patients

  • Nadler does not plan a third company; he wants to remove medical error from the top 10 causes of US deaths

1. Back at Goldman

The host welcomed Nadler back to Goldman Sachs.

Goldman incubated his first company

"But the closest thing that I ever had to a real job was when I started my first company and Goldman basically incubated that company. It was called Kensho Technologies." — Daniel Nadler

The host noted that he sold Kensho in 2018 for $700 million, which she said was the highest price any company had fetched at the time, while he was in his 30s.

2. A Haystack Doubling Monthly

User's avatar

Continue reading this post for free, courtesy of Scuttlebutt.

Or purchase a paid subscription.
© 2026 The Golden Age LLC · Privacy ∙ Terms ∙ Collection notice
Start your SubstackGet the app
Substack is the home for great culture